Phenotypic changes in neutrophil granulocytes of healthy donors after G-CSF administration.
OBJECTIVE
The aim of the present work was to analyze the immunophenotypic changes in neutrophil granulocytes (NG) and their evolution over time in 16 healthy donors who received G-CSF for stem cell mobilization for allogeneic peripheral blood stem cells (PBSC) transplantation.


METHODS
The mobilization schedule consisted of G-CSF (Filgrastimq, Amgen) 10 microg/kg, s.c. for five consecutive days. Apheresis began 16-24h after the last dose of G-CSF. Immunophenotypic analysis (CD10, CD14, CD15, CD16, CD71, CD34 and HLA-DR) of NG and measurement of G-CSF serum levels were performed before G-CSF administration (day 0), on the fifth day of G-CSF treatment and days +7 and +30 after the last dose of G-CSF.


RESULTS
After G-CSF administration, peripheral blood NG presented increased expression of HLA-DR, CD34, CD14, and CD71, in addition to decreased expression of CD10 and CD15 and CD16 fluorescence mean intensity. The phenotypic changes on NG were parallel to serum G-CSF levels. All the phenotypic changes returned to the baseline values by one month after the end of G-CSF treatment. No changes were found in the expression of HLA-DR on T and B-lymphocytes.


CONCLUSIONS
These immunophenotypic changes suggest that after G-CSF administration NG from healthy donors who received G-CSF for stem cell mobilization carry transient features of immature phenotype and have increased functional activity.
Zarco
M A
MA
Deparments of Hematology and Clinical Biochemistry Hospital Clinic, Barcelona, Spain.
Ribera
J M
JM
Urbano-Ispizua
A
A
Filella
X
X
Arriols
R
R
Martínez
C
C
Feliu
E
E
Montserrat
E
E
D000328:Adult; D015703:Antigens, CD / Q000032:analysis / Q000187:drug effects; D001782:Blood Donors; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000097:blood; D006098:Granulocytes / Q000187:drug effects* / Q000276:immunology; D006684:HLA-DR Antigens / Q000032:analysis; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
D015703:Antigens, CD; D006684:HLA-DR Antigens; D016179:Granulocyte Colony-Stimulating Factor